The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice
- 7 December 2005
- journal article
- review article
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (2) , 411-421
- https://doi.org/10.1016/j.jhep.2005.12.001
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Isatoribine, an Agonist of TLR7, Reduces Plasma Virus Concentration in Chronic Hepatitis C Infection *Hepatology, 2005
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005
- 91 Virologic response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon α-2aJournal of Hepatology, 2005
- The Pathway of HCV IRES-Mediated Translation InitiationCell, 2004
- Structural biology of hepatitis C virusHepatology, 2004
- Oligonucleotide-based Strategies to Inhibit Human Hepatitis C VirusOligonucleotides, 2003
- Role of the Asialoglycoprotein Receptor in Binding and Entry of Hepatitis C Virus Structural Proteins in Cultured Human HepatocytesJournal of Virology, 2003
- Activation and Deactivation of a Broad-Spectrum Antiviral Drug by a Single Enzyme: Adenosine Deaminase Catalyzes Two Consecutive Deamination ReactionsAntimicrobial Agents and Chemotherapy, 2003
- Ultrastructural observations of viral particles within hepatitis C virus-infected human B lymphoblastoid cell lineResearch in Virology, 1997
- Patients Infected with the Same Hepatitis C Virus Strain Display Different Kinetics of the Isolate-Specific Antibody ResponseThe Journal of Infectious Diseases, 1997